Pharma News

In a major step toward improving global pandemic preparedness, Swiss pharmaceutical giant Roche and the Medicines Patent Pool (MPP) have signed a voluntary licensing agreement to expand access to the influenza antiviral drug Xofluza (baloxavir marboxil) across 129 low and middle-income countries (LMICs).

Merck has announced encouraging Phase 3 results for its investigational cancer therapy sacituzumab tirumotecan (sac-TMT), offering new hope for patients with advanced or recurrent endometrial cancer who have limited treatment options after standard therapies fail.

The company revealed that the global TroFuse-005 clinical trial successfully achieved its two primary goals, improving overall survival (OS) and progression-free survival (PFS), when compared with conventional chemotherapy in previously treated patients.

Novartis announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.

Researchers have uncovered a surprising new mechanism behind memory loss in Alzheimer’s disease, identifying dopamine deficiency as a major contributor to cognitive decline. The discovery could open the door to new treatment approaches aimed at restoring memory in patients suffering from the disease.

The study was led by scientists at Tohoku University in collaboration with researchers from the University of California, Irvine. Their findings were published in the journal Nature Neuroscience on April 23, 2026.

A major breakthrough in diabetes research could one day free patients with type 1 diabetes from lifelong insulin injections. Researchers from Université de Genève and Geneva University Hospitals have developed an innovative protective hydrogel capable of supporting insulin-producing cells after transplantation, successfully restoring blood sugar control in diabetic mice.

Indian drug maker Alembic Pharmaceuticals has reported a strong financial performance for the fourth quarter of FY26, driven by steady growth in domestic formulations, robust US business expansion, and its strategic entry into the branded pharmaceuticals segment in the United States.

In a significant regulatory achievement, Alembic Pharmaceuticals has successfully cleared a Good Manufacturing Practices (GMP) inspection conducted by Brazil’s health regulatory authority, ANVISA, for its API-III manufacturing facility located at Karakhadi, Gujarat.

According to the company’s regulatory filing submitted to stock exchanges on May 15, 2026, the inspection was carried out from May 11 to May 15, 2026, and concluded without any observations.

India-based pharmaceutical giant Dr. Reddy's Laboratories has announced the launch of its generic Semaglutide Injection in Canada, becoming one of the first companies to introduce the product in the Canadian market following approval from Health Canada.

The World Health Organization has officially declared the ongoing Ebola outbreak in the Democratic Republic of the Congo and Uganda a “Public Health Emergency of International Concern” (PHEIC), raising global alarm over the rapid spread of the deadly virus across Central Africa.